Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048007 | 0.82 | MAPT (0.40) | L3MBTL1CDK4CCND1MEN1KMT2A | |
| SCHEMBL4940436 | 0.82 | DRD2 (0.40) | CDK4CCND1MEN1KMT2AACHE | |
| SCHEMBL12424155 | 0.82 | MAPT (0.40) | L3MBTL1CDK4CCND1MEN1KMT2A | |
| SCHEMBL4940440 | 0.82 | DRD2 (0.40) | CDK4CCND1MEN1KMT2AACHE | |
| SCHEMBL1048008 | 0.82 | MAPT (0.40) | L3MBTL1CDK4CCND1MEN1KMT2A | |
| SCHEMBL13380438 | 0.78 | MAPK1 (0.50) | L3MBTL1CDK4CCND1HPGDMAPK1 | |
| SCHEMBL29310070 | 0.78 | L3MBTL1 (0.41) | L3MBTL1MGLLHPGDMCOLN3MAPK1 | |
| SCHEMBL29310074 | 0.78 | L3MBTL1 (0.41) | L3MBTL1MGLLHPGDMCOLN3MAPK1 | |
| SCHEMBL25839399 | 0.78 | L3MBTL1 (0.41) | L3MBTL1MGLLHPGDMCOLN3MAPK1 | |
| SCHEMBL23544823 | 0.77 | L3MBTL1 (0.34) | L3MBTL1NOTUMMEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | L3MBTL1 4396/4885MGLL 4420/4885CDK4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.